Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients …
TORONTO—-Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D Immune Globulin Intravenous for mild-to-moderate Alzheimer’s disease.
Read more on Business Wire via Yahoo! Finance
